Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 2/20 | 0.55 |
| ▸ | FEN1 | P39748 | 2/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22041457 | 0.81 | ERCC5 (0.62) | ERCC5FEN1ADORA2B | |
| SCHEMBL14945516 | 0.80 | ERCC5 (0.52) | ERCC5FEN1ADORA2B | |
| SCHEMBL20867527 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL30096498 | 0.77 | ERCC5 (0.51) | ERCC5FEN1ADORA2B | |
| SCHEMBL20220467 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL14945135 | 0.76 | ACACB (0.38) | — | |
| SCHEMBL16372199 | 0.74 | CNOT7 (0.31) | — | |
| SCHEMBL20867526 | 0.74 | ALDH1A1 (0.31) | — | |
| SCHEMBL20867639 | 0.74 | ALDH1A1 (0.31) | ADORA2B | |
| SCHEMBL14945492 | 0.74 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571205-B1 | THIENOPYRIMIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| EP-3660023-B1 | THIENOPYRIMIDINEDIONE COMPOUNDS AS ACC INHIBITORS AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2023-03-08 | — | — | EP | disclosed |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-10759812-B2 | Thienopyrimidine derivative and use thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| EP-3660023-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660023-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-20200165265-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2017091600-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ERCC5 2207/4885FEN1 1343/4885ADORA2B 3395/4885 |
| US-20200165265-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | ACACA, ACACB, ACAT2 | ERCC5 3763/4885FEN1 1442/4885ADORA2B 3844/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ERCC5 2207/4885FEN1 1343/4885ADORA2B 3395/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ERCC5 2207/4885FEN1 1343/4885ADORA2B 3395/4885 |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | ACACA, ACACB, PC | ERCC5 3079/4885FEN1 1379/4885ADORA2B 3341/4885 |
| US-10759812-B2 | Thienopyrimidine derivative and use thereof in medicine | ACACA, ACACB, PC | ERCC5 1078/4885FEN1 889/4885ADORA2B 862/4885 |
| US-11186587-B2 | Compound as ACC inhibitor and use thereof | ACACA, ACACB, ACAT2 | ERCC5 3763/4885FEN1 1442/4885ADORA2B 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.